Blood-Based Surveillance Monitoring of Circulating Tumor DNA From Patients With SCLC Detects Disease Relapse and Predicts Death in Patients With Limited-Stage Disease

Blood-Based Surveillance Monitoring of Circulating Tumor DNA From Patients With SCLC Detects Disease Relapse and Predicts Death in Patients With Limited-Stage Disease

Introduction: Most patients (70%) with limited-stage SCLC (LS-SCLC) who are treated with curative-intent therapy suffer disease relapse and cancer-related death. We evaluated circulating tumor DNA (ctDNA) as a predictor of disease relapse and death after definitive therapy in patients with LS-SCLC....

Full description

Bibliographic Details
Main Authors: Wade T. Iams, MD, Prasad R. Kopparapu, PhD, Yingjun Yan, MS, Anel Muterspaugh, MPH, Zhiguo Zhao, MS, Heidi Chen, PhD, Christopher Cann, MD, Sally York, MD, PhD, Leora Horn, MD, MS, Kristin Ancell, MD, Kenneth Wyman, MD, Caterina Bertucci, MPA, Tristan Shaffer, MS, Lauren A. Hodsdon, MPH, Kavita Garg, PhD, Seyed Ali Hosseini, MD, PhD, Lee P. Lim, PhD, Christine M. Lovly, MD, PhD
Format: Article
Language:English
Published: Elsevier 2020-06-01
Series:JTO Clinical and Research Reports
Subjects:
Small cell lung cancer
Circulating tumor DNA
Minimal residual disease
Liquid biopsy
Next-generation sequencing
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364320300242

Internet

http://www.sciencedirect.com/science/article/pii/S2666364320300242

Similar Items